Amgen (AMGN)

Hold Current rating · 4 reports

Coverage summary

Aardvark Labs Capital Research has covered Amgen (AMGN) since February 4, 2026. The company is in the Healthcare sector. This page lists 4 reports: 4 earnings recaps.

The latest is the Q3 2026 Earnings Recap, published November 4, 2026. The current rating is Hold, the same in every report since coverage began.

Translations: 3 in Chinese.

All AMGN reports

2026-11-04

Hold Recap: Q3 2026

Three Phase 3 Wins Lift Amgen's Growth Case Beyond MariTide, but Denosumab Steepens to a 45% Decline and the Stock Already Trades at 20.5x

2026-08-05

Hold Recap: Q2 2026

Amgen Answers the Quality Question: Product Sales Accelerate to 9%, the Raise Beats the Beat, and the Discount Closes

2026-05-01

Hold Recap: Q1 2026

Amgen's Beat-and-Raise Gets Sold: Low-Quality Composition and Two Fresh Overhangs Outweigh a Cheaper Stock

2026-02-04

Hold Recap: Q4 2025

Amgen's Double Beat and Above-Street 2026 Guide Reprice the Stock 8%; MariTide Remains the Whole Ballgame